Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 9/20 | 0.60 |
| ▸ | BCL2 | P10415 | 10/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5131603 | 0.99 | BCL2L1 (0.59) | BCL2L1BCL2DRD2DRD4CETP | |
| SCHEMBL5128722 | 0.93 | BCL2L1 (0.61) | BCL2L1BCL2CETP | |
| SCHEMBL5128718 | 0.93 | BCL2L1 (0.61) | BCL2L1BCL2CETP | |
| Hydrochloric Acid SCHEMBL5129185 | 0.92 | BCL2L1 (0.60) | BCL2L1BCL2CETP | |
| SCHEMBL30857750 | 0.86 | BCL2L1 (0.58) | BCL2L1BCL2CETP | |
| SCHEMBL30857660 | 0.86 | BCL2L1 (0.58) | BCL2L1BCL2CETP | |
| SCHEMBL3819200 | 0.85 | DRD3 (0.40) | BCL2L1DRD2DRD4 | |
| SCHEMBL4787539 | 0.85 | DRD3 (0.40) | BCL2L1DRD2DRD4 | |
| SCHEMBL30857714 | 0.84 | BCL2L1 (0.57) | BCL2L1BCL2CETP | |
| Hydrochloric Acid SCHEMBL5129273 | 0.82 | DRD2 (0.49) | DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1953161-B1 | New tricyclic derivatives, method of preparing same and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008110691-A1 | NOVEL TRICYCLIC DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2008-09-18 | — | — | WO | disclosed |
| US-20080188460-A1 | Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2008-08-07 | — | — | US | disclosed |
| EP-1953161-A1 | New tricyclic derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188460-A1 | Tricyclic compounds, a process for their preparation and pharmaceutical compositions containing them | BAX, BCL2, CASP3 | BCL2L1 45/4885BCL2 2/4885DRD2 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.